| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000026506 |
| Receipt No. | R000030441 |
| Scientific Title | clinical study of the autologous oral mucosal epithelial cell sheets in preventing formation of strictures after endoscopic submucosal dissection for esophageal cancer |
| Date of disclosure of the study information | 2017/05/01 |
| Last modified on | 2019/09/19 (Ver. 3) |
| Basic information | ||
| Public title | clinical study of the autologous oral mucosal epithelial cell sheets in preventing formation of strictures after endoscopic submucosal dissection for esophageal cancer | |
| Acronym | Churaumi Study | |
| Scientific Title | clinical study of the autologous oral mucosal epithelial cell sheets in preventing formation of strictures after endoscopic submucosal dissection for esophageal cancer | |
| Scientific Title:Acronym | Churaumi Study | |
| Region |
|
|
| Condition | |||
| Condition | Case with esophageal stricture following ESD treatment for early esophageal cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The safety of transplanting an autologous oral mucosal epithelial cell sheet to the lacrimal injury arising when balloon dilation is performed against esophageal stricture after ESD treatment for early esophageal cancer and its effectiveness in preventing esophageal narrowing |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | Safety of Oral Mucosal Epithelial Cell Sheet |
| Key secondary outcomes | Preventive effect of esophageal narrowing by oral mucosal epithelial cell sheet transplantation |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral mucosa and peripheral blood are collected from the patient, an oral mucosa epithelial cell sheet is prepared from the collected oral mucosa and peripheral blood, and transplanted to a laceration site after balloon dilation using an endoscope | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients aged 20 years or older.
2) Patients with esophageal stenosis that occurred after ESD treatment for early esophageal cancer. 3) Patients whose main organ function is kept as a rule as below (data within 1 month before registration). Leukocyte count >= 4,000 <= 10,000 Platelet count >= 100,000 Serum AST (GOT) and ALT (GPT) <= 100 Serum total bilirubin <= 2.0 Serum creatinine <= 2.0 In the above, the inspection standard value of the currently practiced esophageal regeneration cell sheet trial was adopted. However, if it is considered that the reason for not satisfying the above is based on the original disease, it can be selected according to the judgment of the research representative. |
|||
| Key exclusion criteria | 1) Patients with complications of poor control
(Heart disease, liver disease, kidney disease, cerebral infarction, etc.). 2)Patients with pregnancy, lactating women and possibility (intention) of pregnancy. 3)A patient with a history of serious drug allergy. 4)Patients infected with infectious diseases (hepatitis B, hepatitis C, HIV, HTLV-1, syphilis). 5)A patient who has a disease in the oral mucosa at the tissue collection site and is unable to collect it. 6)Other patients who are deemed inappropriate by the research representative. |
|||
| Target sample size | 6 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Tomishiro Central Hospital | ||||||
| Division name | Gastroenterology | ||||||
| Zip code | 9010243 | ||||||
| Address | 25 aza ueda tomigusuku-shi okinawa prefecture | ||||||
| TEL | 098-850-3811 | ||||||
| akatou@yuuai.or.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tomishiro Central Hospital | ||||||
| Division name | Advanced Medical Research Center | ||||||
| Zip code | 9010243 | ||||||
| Address | 25 aza ueda tomigusuku-shi okinawa prefecture | ||||||
| TEL | 098-850-3811 | ||||||
| Homepage URL | |||||||
| ochiai.tomishirocentaral.hp@gmail.com | |||||||
| Sponsor | |
| Institute | Tomishiro Central Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | okinawa prefecture |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kyushu University Specific Regenerative Medicine Committee |
| Address | 3-1-1 umade higasiku hukuoka-city |
| Tel | 092-642-5082 |
| byshasiwatas@jimu.kyushu-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 豊見城中央病院(沖縄県)、中頭病院(沖縄県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030441 |